Examination of anti-fibrotic and immune modulatory effects of OXY210 for targeting cystic fibrosis
Active Grant Awarded
- Award ID
- R43HL184363
- Recipient
-
Max Biopharma, Inc. UEI NZ8XY5DKRAD3
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $364,853
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 21% complete
- Place of performance
- Santa Monica, CA 90404, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health, through its National Heart, Lung, and Blood Institute, awarded Grant R43HL184363 to Max Biopharma, Inc., obligating $364,853 on September 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds an examination of the anti-fibrotic and immune modulatory effects of OXY210, an orally bioavailable oxysterol derivative, for targeting cystic fibrosis. The abstract reports OXY210 as efficacious in mouse models of liver and lung fibrosis and inflammation, and frames the study around hyperinflammatory macrophage dysfunction that cystic fibrosis CFTR modulator therapies leave unaddressed. The ultimate completion date is August 31, 2027. Place of performance is Santa Monica, CA 90404.
Description
- Abstract
- Cystic fibrosis (CF), a devastating genetic disease affecting the lungs and other organs, is characterized by severe chronic hyperinflammatory responses in the lungs that culminate in respiratory failure and death. CF is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Mutated CFTR proteins show impaired function as transport proteins, causing salt imbalances and dehydration of surface liquids in secretory and respiratory epithelia. In lung tissue, dehydration of airway surface liquids produces buildup of thick mucus, which is prone to infection, leading to airway obstruction and a pro- inflammatory airway milieu. CF hyperinflammatory responses are driven by the innate immune system and due in large part to disease altered functions of CF monocytes and macrophages associated with an increased metabolic state. CFTR modulator therapies have produced significant clinical benefits in people with cystic fibrosis (PWCF) harboring responsive CFTR variants, linked to the rescued function of mutated CFTR proteins in bronchial epithelial cells. Although not designed for this purpose, modulator therapy drugs can also affect CF inflammation through a combination of direct and indirect effects but leave a significant portion of hyperinflammatory macrophage dysfunction unaddressed. Auxiliary immunomodulatory and anti-fibrotic therapies, used alone or combined with CFTR modulator drugs, could help improve clinical outcomes in PWCF. We have identified and characterized OXY210, an orally bioavailable oxysterol derivative with immunomodulatory, anti-fibrotic and drug-like properties, as efficacious in mouse models of liver and lung fibrosis and inflammation, mediated in part by inhibition of TGF-Β-induced pro-fibrotic responses and toll-like receptor signaling mediated inflammatory responses in macrophages, respectively. In recent studies we found immunomodulatory effects of OXY210 in monocytes derived from PWCF that exhibit hyperinflammatory responses to lipopolysaccharide (LPS) stimulation, assessed by the inhibition of production of inflammatory cytokines IL-1Β and TNF-Α. We hypothesize that, based on its mechanism of action, OXY210 may reduce hyperinflammation associated with CF, when used alone or in combination with CFTR modulators. In this application, we propose to examine OXY210, as a potential CF drug candidate when used alone or in combination with CFTR modulator, ETI (elexacaftor+tezacaftor+ivacaftor), using human airway-like macrophages (ALM) exposed to microbial pathogens and/or LPS EX vivo, and in humanized mice that harbor the F508DEL mutated CFTR gene infected with pseudomonas aeruginosa. We will assess peak inflammatory responses, inflammation resolution, fibrosis, and bacterial clearance post bacterial infection. To achieve our goals and test our hypothesis we propose the following specific aims: aim 1. Elucidate the effects of OXY210 on the inflammatory and pro-fibrotic responses of transmigrated ALM derived from PWCF EX vivo; and aim 2. Examine disease modifying effects of OXY210 in humanized F508DEL/F508DEL repeat infection mouse model.
Quick answers
Who received award R43HL184363?
R43HL184363 was awarded to Max Biopharma, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 9, 2026.
How much is award R43HL184363 worth?
$364,853 has been obligated on R43HL184363.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award